Promoting the use of oral ondansetron in children receiving cancer chemotherapy

American Journal of Health-System Pharmacy

Volumn 58, Issue 7, 2001, Pages 598-602

  Walker, P C ^a   Biglin, K E ^a   Constance, T D ^a   Bhambhani, K ^a   Sims Mccallum, R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANISETRON; ONDANSETRON; SEROTONIN ANTAGONIST;

AGITATION; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG PACKAGING; DRUG TOLERABILITY; DRUG USE; FATIGUE; HEADACHE; HUMAN; INJECTION; MALAISE; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEDATION; TREATMENT OUTCOME; VERTIGO;

EID: 0035313854     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.7.598     Document Type: Article

References (22)

1. Efficacy, pharmacokinetics, and safety of ondansetron in pediatric chemotherapy patients
2. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia
3. 5HT3 antagonist ondansetron - An effective outpatient antiemetic in cancer treatment
4. The role of ondansetron in paediatric patients: A review of three studies
5. Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children
6. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia
7. Randomized double-blind crossover ondansetron-dexamethasone vs. ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies
8. Randomized comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis
9. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation
10. Program for controlling use of ondansetron injection
11. Evaluation of ondansetron prescribing in U.S. academic medical centers
12. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting
13. Impact of ondansetron prescribing guidelines on patient outcome and pharmacy expenditure
14. Antiemetic guidelines for oncology patients using granisetron and ondansetron: An efficacy and cost analysis
15. Assessing the pharmacoeconomic impact of innovative ondansetron dosing regimes in the inpatient and outpatient oncology units
16. 3 antagonists in the prevention of nausea and vomiting in children
17. A comparison of oral ondansetron syrup and intravenous ondansetron regimens given in combination with oral dexamethasone for the prevention of emesis and nausea in paediatric patients receiving moderately/highly emetogenic chemotherapy
18. Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery
19. Ondansetron clinical pharmacokinetics
20. Pharmacokinetics of ondansetron in patients with hepatic insufficiency
21. Pharmaceutical development of ondansetron tablets
22. Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients